Jazz Pharmaceuticals Gets FDA Priority Review For Ziihera In Gastric Cancers

Jazz Pharmaceuticals said the FDA granted priority review to its supplemental BLA for Ziihera as a first-line treatment for adults with HER2-positive gastric and gastroesophageal cancer. Priority review shortens the regulatory timeline and signals the filing has potential merit, although no approval decision has been announced yet. The update is constructive for Jazz but remains a regulatory step rather than a final commercial catalyst.

Analysis

Jazz Pharmaceuticals said the FDA granted priority review to its supplemental BLA for Ziihera as a first-line treatment for adults with HER2-positive gastric and gastroesophageal cancer. Priority review shortens the regulatory timeline and signals the filing has potential merit, although no approval decision has been announced yet. The update is constructive for Jazz but remains a regulatory step rather than a final commercial catalyst.